Pleiomutinine






Names

    • Pleiomutinine

Attributes

  • Canonical SMILES

    C/C=C\1/CN2CC[C@@]34CN5C6=C(C=CC=C6[C@@]37[C@@H]2C[C@@H]1[C@H](N7C8=CC=CC=C48)C(=O)OC)[C@@]91[C@@]52CC[C@@]3([C@H]2C)[C@@H]9N(CCC3)CC1

  • InChI

    InChI=1S/C40H46N4O2/c1-4-25-22-42-19-16-37-23-43-33-28(38-17-20-41-18-8-13-36(35(38)41)14-15-39(38,43)24(36)2)10-7-11-29(33)40(37)31(42)21-26(25)32(34(45)46-3)44(40)30-12-6-5-9-27(30)37/h4-7,9-12,24,26,31-32,35H,8,13-23H2,1-3H3/b25-4-/t24-,26+,31+,32+,35+,36+,37+,38-,39+,40-/m1/s1

  • Molecule Class: Alkaloids
  • TPSA: 39.26
  • #RotBonds: 1
  • MW: 614.834
  • HBD: 0
  • HBA: 6
  • logP: 5.343800000000006
  • Chemical Formula: C40H46N4O2


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. contorta Cameroon 761060 N43440/HNC

External Databases


References

  • Indoline alkaloids from Tabernaemontana contorta with cancer chemopreventive activity. Phytochemistry, 2017 (PMID 28950224).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Inhibitory
    • Cancer chemopreventive

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -5.53
    Human Oral Bioavailability 20% Non-Bioavailable
    Human Intestinal Absorption Absorbed
    Madin-Darby Canine Kidney -1.61
    Human Oral Bioavailability 50% Non-Bioavailable
    P-Glycoprotein Inhibitor Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability 470.72
    Distribution Blood-Brain Barrier (Central Nervous System) -2.65
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 1.69
    Plasma Protein Binding 89.78
    Steady State Volume of Distribution 4.82
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Non-Inhibitor
    CYP 1A2 substrate Non-Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Non-Substrate
    CYP 2C9 Inhibitor Non-Inhibitor
    CYP 2C9 Substrate Non-Substrate
    CYP 2D6 Inhibitor Non-Inhibitor
    CYP 2D6 Substrate Substrate
    CYP 3A4 Inhibitor Non-Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Non-Inhibitor
    Excretion Clearance 3.54
    Organic Cation Transporter 2 Non-Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Safe
    Avian Toxic
    Bee Toxic
    Bioconcentration Factor -8.47
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Toxic
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -0.45
    Liver Injury II Toxic
    hERG Blockers Toxic
    Daphnia Maga 6.64
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Toxic
    T. Pyriformis -857032.25
    Rat (Acute) 4.32
    Rat (Chronic Oral) 1.6
    Fathead Minnow 1085.26
    Respiratory Disease Toxic
    Skin Sensitisation Toxic
    SR-ATAD5 Toxic
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Safe
    General Properties Boiling Point 94450.19
    Hydration Free Energy -2.92
    Log(D) at pH=7.4 4.35
    Log(P) 4.75
    Log S -4.83
    Log(Vapor Pressure) -3027.92
    Melting Point 343.45
    pKa Acid 2.35
    pKa Basic 8.12